Kodiak's Eylea rival hits 'major disappointment' with failure in first of 6 phase 3 studies

Kodiak Sciences' attempt to rival Regeneron and Bayer's blockbuster drug Eylea, KSI-301, has flopped the first in a series of six phase 3 studies, casting an ominous cloud over the rest of the program.